BioNTech co-founders Uğur Şahin and Özlem Türeci will step down from management to launch a new venture focused on mRNA technologies. The management changes come as BioNTech announced a 57% increase in net losses for 2025. The company plans to develop vaccines to treat cancer by 2030. These vaccines will be based on the mRNA technology that Şahin and Türeci participated in. BioNTech is a German company known for its work in the field of vaccines.